Phaseline

Companies › Servier Affaires Médicales

Servier Affaires Médicales: clinical trials, targets and expected readouts

1 active drug program in 31 registered trials: 15 Phase 2, 10 Phase 1, 6 Phase 3; Hematology, Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ivosidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 3Acute Myeloid Leukemia (AML); Cholangiocarcinoma; Newly Diagnosed Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia …Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02632708IvosidenibPhase 1Newly Diagnosed Acute Myeloid Leukemia (AML)HematologyDec 2018
NCT03173248IvosidenibPhase 3Newly Diagnosed Acute Myeloid Leukemia (AML)OncologyMar 2021
NCT07282262IvosidenibPhase 2Biliary Tract CancerOncologyOct 2026
NCT07007949IvosidenibPhase 2Acute Myeloid LeukemiaOncologyDec 2026
NCT05010772IvosidenibPhase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT02074839IvosidenibPhase 1Relapsed or Refractory Acute Myeloid Leukemia (AML)OncologyDec 2026
NCT05209074IvosidenibPhase 1Pancreatic Ductal AdenocarcinomaOncologyDec 2026
NCT03155620IvosidenibPhase 2Advanced Malignant Solid NeoplasmOncologyJan 2027
NCT04278781IvosidenibPhase 2ChondrosarcomaOncologyMar 2027
NCT03503409IvosidenibPhase 2Myelodysplastic SyndromesOncologyApr 2027
NCT03839771IvosidenibPhase 3Acute Myeloid LeukemiaOncologyApr 2027
NCT05756777IvosidenibPhase 1Acute Myeloid Leukemia (AML)OncologyApr 2027
NCT04195555IvosidenibPhase 2Recurrent EpendymomaOncologyMay 2027
NCT07607418IvosidenibPhase 2AML (Acute Myeloid Leukemia)HematologyMay 2027
NCT05615818IvosidenibPhase 3Biliary Tract NeoplasmsOncologyJun 2027
NCT06501625IvosidenibPhase 1Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationOncologySep 2027
NCT05401097IvosidenibPhase 2Acute Myeloid LeukemiaOncologySep 2027
NCT03471260IvosidenibPhase 1Acute Myeloid LeukemiaOncologySep 2027
NCT05907057IvosidenibPhase 3Acute Myeloid Leukemia (AML)OncologyOct 2027
NCT06465953IvosidenibPhase 3Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)HematologyNov 2027
NCT04774393IvosidenibPhase 1Acute Myeloid LeukemiaOncologyNov 2027
NCT05876754IvosidenibPhase 3CholangiocarcinomaOncologyDec 2027
NCT06707493IvosidenibPhase 2IDH1 MutationOncologyJan 2028
NCT07392242IvosidenibPhase 2Acute Myeloid LeukemiaOncologyJan 2028
NCT04493164IvosidenibPhase 2Acute Myeloid Leukemia With Gene MutationsOncologyJun 2028
NCT06611839IvosidenibPhase 1AMLOncologyOct 2028
NCT07507760IvosidenibPhase 2Acute Myeloid Leukemia With Gene MutationsOncologyApr 2029
NCT06291987IvosidenibPhase 1Myeloproliferative NeoplasmsOncologyMay 2029
NCT06717958IvosidenibPhase 2AMLOncologyOct 2029
NCT05030441IvosidenibPhase 2Clonal Cytopenia of Undetermined SignificanceOncologyJan 2030
NCT07260175IvosidenibPhase 2CholangiocarcinomaOncologyDec 2030

Targets

IDH1 (1)

Companies with the same targets

Servier Eli Lilly Nuvation Bio Bristol-Myers Squibb Kissei Pharmaceutical Hutchmed Rigel Pharmaceuticals Servier Bio-Innovation Novartis Daiichi Sankyo

Companies built like this

Servier Institut de Recherches Internationales Servier (I.R.I.S.) Geron Syntrix Biosystems Electra Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.